Shanghai Ultra-T Immune Therapeutics

Ultra-T Immune is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the development of transformative T cell therapies for autoimmune diseases and cancer. The company was founded by Dr. Song-Guo Zheng, a pioneer in regulatory T cell (Treg) research, and leverages its proprietary Ultra-T platform to engineer highly potent and stable cell products. Its lead candidate, UTJS-001, is a CD19-targeted CAR-T therapy currently undergoing clinical evaluation for the treatment of systemic lupus erythematosus (SLE). Beyond SLE, the company is expanding its pipeline to include therapies for other immune-mediated disorders and solid tumors, aiming to provide long-term remission for patients with high unmet medical needs.